FDA has granted market clearance to Memorial Sloan Kettering Cancer Center’s integrated mutation profiling of actionable cancer targets tumor profiling test, an in vitro diagnostic that can identify a greater number of genetic mutations in various cancers than any test previously reviewed by the agency.
Read More
The cancers that the test screens for—cancers of the breast, colorectum, esophagus, liver, lung, ovary, pancreas, and stomach—account for more than 60% of cancer deaths in the United States.
Read More
Dry slide technology does not require water, plumbing and drains, or the need to dispose of water as medical waste.
Read More
Agendia and Bluebee have partnered to provide a secure data processing solution for Agendia’s MammaPrint BluePrint breast cancer recurrence and molecular subtyping kit.
Read More
The acquisition of FTD increases the menu of the Siemens Healthineers Versant kinetic polymerase chain reaction molecular system by more than 80 assays and syndromic panels.
Read More